This uncoupling is clinically relevant because it suggests the bone density changes seen in the Hansen trial are not simply a transient effect of weight loss but may reflect a direct or indirect metabolic effect of GLP-1 receptor activation on bone turnover
These Statements have not been reviewed or approved by the FDA
Li Z, Li S, Wang N, Xue P, Li Y
How long does Gelatine Sculpt take to show results
Celiac disease and autoimmune thyroid disease
However, this outcome fell short of the anticipated 25% weight reduction, potentially limiting its competitive edge against Eli Lillys ZEPBOUND, which reported up to 20.9% weight loss in the SURMOUNT-1 trial. In the subsequent REDEFINE 2 trial, which focused on adults with obesity or overweight and type 2 diabetes, CagriSema achieved a 15.7% mean weight loss after 68 weeks, compared to 3.1% with placebo